Today: 22 January 2026
Subscribe
Browse Category

SGX:9CI News 18 January 2026 - 22 January 2026

CapitaLand Investment (SGX:9CI) pops back above S$3, eyes 52-week high in Singapore trade

CapitaLand Investment (SGX:9CI) pops back above S$3, eyes 52-week high in Singapore trade

Singapore, Jan 22, 2026, 15:08 SGT — Regular session CapitaLand Investment gained 2.4% to close at S$3.01 on Thursday, recovering from yesterday’s drop and edging closer to its 52-week peak of S$3.03. Shares fluctuated between S$2.95 and S$3.03 during the session. (Investing) This matters as the stock nears the upper boundary of its one-year trading range, with investors eyeing upcoming…
22 January 2026
·····
Why CapitaLand Investment stock is down today — and what to watch before Feb 11 results (SGX:9CI)

Why CapitaLand Investment stock is down today — and what to watch before Feb 11 results (SGX:9CI)

SINGAPORE, Jan 21, 2026, 15:34 SGT — Regular session Shares of CapitaLand Investment Limited slipped 1.35% to S$2.93 by 3:18 p.m. local time on Wednesday afternoon. (SG Investors) The pullback unfolded as investors shifted into a defensive posture — a “risk-off” move — following renewed geopolitical tensions and tariff chatter that unsettled markets. “The ‘sell America’ trade fueled major market…
21 January 2026
····
CapitaLand Investment stock price: 9CI sits at S$2.92 as rates and REIT results take the wheel

CapitaLand Investment stock price: 9CI sits at S$2.92 as rates and REIT results take the wheel

Singapore, Jan 18, 2026, 15:37 SGT — The market has closed. CapitaLand Investment Limited shares (SGX:9CI) closed last Friday steady at S$2.92. With no trading over the weekend, there’s little fresh news to sway the stock ahead of Monday’s session. (Capitalandinvest) Why it matters now: Investors have refocused on the rate tape. Strong U.S. data is raising doubts about imminent…
18 January 2026
····

Stock Market Today

  • Pro Medicus Leverages US Market to Strengthen Competitive Edge in Health-Tech
    January 22, 2026, 5:15 AM EST. Pro Medicus (ASX:PME), known for its advanced radiology imaging software and AI capabilities, is strengthening its position in the US hospital market through long-term contracts. The company competes effectively against larger legacy vendors, supporting its premium valuation despite recent share price declines. Investor focus centers on Pro Medicus' ability to sustain contract wins, margins, and cash flow ahead of its February 12, 2026 earnings report. Market sentiment remains fragile amid high valuation risks and expectations. Divergent fair value estimates, ranging from A$68.65 to over A$500, highlight varying investor perspectives on its growth prospects and US footprint. Pro Medicus' premium positioning in the specialized health-tech arena underpins its broader investment narrative.
Go toTop